Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.10 +4.8%	$1.25	$0.81 ▼ $2.10	$26.02M	0.8	248,020 shs	866,788 shs
KPTI Karyopharm Therapeutics	$6.50 +4.5%	$4.42	$3.51 ▼ $16.95	$56.36M	0.28	127,722 shs	312,412 shs
RNAZ TransCode Therapeutics	$10.13 +3.4%	$9.43	$6.15 ▼ $739.20	$8.45M	1.46	196,386 shs	14,272 shs
XLO Xilio Therapeutics	$0.66 -2.7%	$0.69	$0.62 ▼ $1.70	$34.39M	-0.15	2.09 million shs	487,262 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	-16.00%	-33.12%	-11.76%	+7.20%	-16.67%
KPTI Karyopharm Therapeutics	+11.27%	+54.73%	+61.56%	+32.34%	-49.07%
RNAZ TransCode Therapeutics	-6.67%	-14.86%	-1.41%	+23.43%	-99.88%
XLO Xilio Therapeutics	-3.58%	-2.61%	-5.58%	-18.36%	-25.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	3.3112 of 5 stars	3.7	5.0	0.0	2.9	0.8	0.6
KPTI Karyopharm Therapeutics	3.8594 of 5 stars	3.4	0.0	4.6	2.4	2.5	0.6
RNAZ TransCode Therapeutics	2.0925 of 5 stars	3.5	2.0	0.0	2.8	0.0	0.6
XLO Xilio Therapeutics	2.7338 of 5 stars	3.7	2.0	0.0	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	809.09% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	423.08% Upside
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,664.07% Upside
XLO Xilio Therapeutics	3.33	Buy	$3.00	352.08% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, XLO, KPTI, and ENLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/6/2025	XLO Xilio Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	XLO Xilio Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$2.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.39	N/A	N/A	($27.55) per share	-0.24
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$7.37 per share	N/A
XLO Xilio Therapeutics	$15.00M	2.29	N/A	N/A	$0.14 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-378.30%	-186.01%	N/A
XLO Xilio Therapeutics	-$58.24M	-$0.76	N/A	N/A	N/A	-374.79%	-399.15%	-58.68%	11/6/2025 (Estimated)

Latest RNAZ, XLO, KPTI, and ENLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RNAZ TransCode Therapeutics	-$8.68	-$4.94	+$3.74	-$5.13	N/A	N/A
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.08	-$0.16	-$0.08	-$0.16	$8.21 million	$8.21 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	7.20	7.20
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
RNAZ TransCode Therapeutics	N/A	5.27	5.20
XLO Xilio Therapeutics	N/A	2.32	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
KPTI Karyopharm Therapeutics	66.44%
RNAZ TransCode Therapeutics	N/A
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
KPTI Karyopharm Therapeutics	2.75%
RNAZ TransCode Therapeutics	0.01%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.43 million	Optionable
RNAZ TransCode Therapeutics	9	834,000	834,000	Not Optionable
XLO Xilio Therapeutics	70	51.83 million	48.56 million	Not Optionable

RNAZ, XLO, KPTI, and ENLV Headlines

Recent News About These Companies

Leerink Partnrs Brokers Decrease Earnings Estimates for XLO

August 18 at 2:13 AM | americanbankingnews.com

XLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatch

August 16, 2025 | marketwatch.com

Xilio Therapeutics (NASDAQ:XLO) Rating Lowered to "Hold" at Wall Street Zen

August 16, 2025 | americanbankingnews.com

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

August 15, 2025 | msn.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 15, 2025 | taiwannews.com.twT

Xilio Revenue Jumps 246 Percent in Q2

August 15, 2025 | aol.comA

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

August 14, 2025 | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 14, 2025 | globenewswire.com

Xilio Therapeutics (XLO) Expected to Announce Quarterly Earnings on Thursday

August 12, 2025 | americanbankingnews.com

Brokers Set Expectations for XLO Q2 Earnings

August 10, 2025 | americanbankingnews.com

Leerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform Recommendation

August 7, 2025 | msn.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, XLO, KPTI, and ENLV Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.10 +0.05 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 +0.00 (+0.45%)

As of 04:18 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Karyopharm Therapeutics NASDAQ:KPTI

$6.50 +0.28 (+4.50%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 -0.04 (-0.54%)

As of 04:18 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

TransCode Therapeutics NASDAQ:RNAZ

$10.17 +0.37 (+3.78%)

As of 04:00 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Xilio Therapeutics NASDAQ:XLO

$0.66 -0.02 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.09%)

As of 04:03 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time